-
1Academic Journal
Συγγραφείς: Margarita P. Zaikina, Maksim I. Tkachev, Veronika V. Kogaj, Elizaveta S. Tabachenkova, Anna A. Kudryavceva, Dmitrij A. Napalkov, Marina I. Sekacheva, Anastasiya A. Sokolova, Маргарита Павловна Заикина, Максим Игоревич Ткачёв, Вероника Валерьяновна Когай, Елизавета Сергеевна Табаченкова, Анна Александровна Кудрявцева, Дмитрий Александрович Напалков, Марина Игоревна Секачева, Анастасия Андреевна Соколова
Συνεισφορές: Авторы заявляют об отсутствии финансирования исследования.
Πηγή: Complex Issues of Cardiovascular Diseases; Том 14, № 1 (2025); 169-179 ; Комплексные проблемы сердечно-сосудистых заболеваний; Том 14, № 1 (2025); 169-179 ; 2587-9537 ; 2306-1278
Θεματικοί όροι: Сердечно-сосудистое заболевание, Venous thrombosis, Arterial thrombosis, Cancer, Cardiovascular disease, Венозный тромбоз, Артериальный тромбоз, Онкологическое заболевание
Περιγραφή αρχείου: application/pdf
Relation: https://www.nii-kpssz.com/jour/article/view/1570/1008; https://www.nii-kpssz.com/jour/article/downloadSuppFile/1570/1851; https://www.nii-kpssz.com/jour/article/downloadSuppFile/1570/1852; https://www.nii-kpssz.com/jour/article/downloadSuppFile/1570/1853; ReFaey K, Tripathi S, Grewal SS, et al. Cancer Mortality Rates Increasing vs Cardiovascular Disease Mortality Decreasing in the World: Future Implications. Mayo Clin Proc Innov Qual Outcomes. 2021;5(3):645-653. doi:10.1016/j.mayocpiqo.2021.05.005; Moslehi JJ. Cardiovascular Toxic Effects of Targeted Cancer Therapies. Longo DL, ed. N Engl J Med. 2016;375(15):1457-1467. doi:10.1056/NEJMra1100265; de Wall C, Bauersachs J, Berliner D. Cardiooncology-dealing with modern drug treatment, long-term complications, and cancer survivorship. Clin Exp Metastasis. 2021;38(4):361-371. doi:10.1007/s10585-021-10106-x; De Boer RA, Meijers WC, Van Der Meer P, Van Veldhuisen DJ. Cancer and heart disease: associations and relations. European J of Heart Fail. 2019;21(12):1515-1525. doi:10.1002/ejhf.1539; Satpathy C, Kumar Mishra T, Singh S, Jha AK. Reverse cardio-oncology: A budding concept. Indian Heart J. 2023;75(6):398-402. doi:10.1016/j.ihj.2023.09.004; Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. Journal of Thrombosis and Haemostasis. 2007;5(3):632-634. doi:10.1111/j.1538-7836.2007.02374.x; Streiff MB, Holmstrom B, Angelini D, et al. Cancer-Associated Venous Thromboembolic Disease, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021;19(10):1181-1201. doi:10.6004/jnccn.2021.0047; Mosarla RC, Vaduganathan M, Qamar A, Moslehi J, Piazza G, Giugliano RP. Anticoagulation Strategies in Patients With Cancer: JACC Review Topic of the Week. J Am Coll Cardiol. 2019;73(11):1336-1349. doi:10.1016/j.jacc.2019.01.017; Pateras I, Giaginis C, Tsigris C, Patsouris E, Theocharis S. NF-κB signaling at the crossroads of inflammation and atherogenesis: searching for new therapeutic links. Expert Opinion on Therapeutic Targets. 2014;18(9):1089-1101. doi:10.1517/14728222.2014.938051; Buziashvili JI, Stilidi IS, Mackeplishvili ST, et al. Cardiovascular and oncological diseases — focus on modifiable risk factors and modern pathogenetic aspects. Annals RAMS. 2023;78(2):132-140. doi:10.15690/vramn8359; Murata M. Inflammation and cancer. Environ Health Prev Med. 2018;23(1):50. doi:10.1186/s12199-018-0740-1; Masoudkabir F, Sarrafzadegan N, Gotay C, et al. Cardiovascular disease and cancer: Evidence for shared disease pathways and pharmacologic prevention. Atherosclerosis. 2017;263:343-351. doi:10.1016/j.atherosclerosis.2017.06.001; Genovesi S, Giussani M, Orlando A, Lieti G, Viazzi F, Parati G. Relationship between endothelin and nitric oxide pathways in the onset and maintenance of hypertension in children and adolescents. Pediatr Nephrol. 2022;37(3):537-545. doi:10.1007/s00467-021-05144-2; Gerotziafas GT, Taher A, Abdel-Razeq H, et al. A Predictive Score for Thrombosis Associated with Breast, Colorectal, Lung, or Ovarian Cancer: The Prospective COMPASS-Cancer-Associated Thrombosis Study. Oncologist. 2017;22(10):1222-1231. doi:10.1634/theoncologist.2016-0414; Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer. 2007;110(10):2339-2346. doi:10.1002/cncr.23062; Khorana AA, Mackman N, Falanga A, et al. Cancer-associated venous thromboembolism. Nat Rev Dis Primers. 2022;8(1):11. doi:10.1038/s41572-022-00336-y; Cohen AT, Katholing A, Rietbrock S, Bamber L, Martinez C. Epidemiology of first and recurrent venous thromboembolism in patients with active cancer: A population-based cohort study. Thromb Haemost. 2017;117(01):57-65. doi:10.1160/TH15-08-0686; Linnemann B, Zgouras D, Schindewolf M, Schwonberg J, Jarosch-Preusche M, Lindhoff-Last E. Impact of sex and traditional cardiovascular risk factors on the risk of recurrent venous thromboembolism: results from the German MAISTHRO Registry. Blood Coagulation & Fibrinolysis. 2008;19(2):159-165. doi:10.1097/MBC.0b013e3282f54558; Wells G, Herrington DM. The Heart and Estrogen/Progestin Replacement Study: What Have We Learned and What Questions Remain? Drugs & Aging. 1999;15(6):419-422. doi:10.2165/00002512-199915060-00001; Jezovnik MK, Poredos P, Lusa L. Idiopathic Venous Thrombosis is Associated with Preclinical Atherosclerosis. JAT. 2010;17(3):304-311. doi:10.5551/jat.3079; Bai J, Ding X, Du X, Zhao X, Wang Z, Ma Z. Diabetes is associated with increased risk of venous thromboembolism: A systematic review and meta-analysis. Thrombosis Research. 2015;135(1):90-95. doi:10.1016/j.thromres.2014.11.003; Zhan Y, Fu X, Bi W, Li G. Risk factors for venous thromboembolism in patients with chronic kidney disease: a systematic review and meta-analysis. Ren Fail. 2024;46(2):2431149. doi:10.1080/0886022X.2024.2431149; Lees JS, Ho F, Parra-Soto S, et al. Kidney function and cancer risk: An analysis using creatinine and cystatin C in a cohort study. eClinicalMedicine. 2021;38:101030. doi:10.1016/j.eclinm.2021.101030; Roach REJ, Lijfering WM, Tait RC, et al. Sex difference in the risk of recurrent venous thrombosis: a detailed analysis in four European cohorts. Journal of Thrombosis and Haemostasis. 2015;13(10):1815-1822. doi:10.1111/jth.13116; Pastori D, Cormaci VM, Marucci S, et al. A Comprehensive Review of Risk Factors for Venous Thromboembolism: From Epidemiology to Pathophysiology. Int J Mol Sci. 2023;24(4):3169. doi:10.3390/ijms24043169
-
2Academic Journal
Πηγή: Лекарства Украины; № 2(258) (2022): приложение 1; 40-43
Medicine of Ukraine; No. 2(258) (2022): appendix 1; 40-43
Ліки України; № 2(258) (2022): додаток 1; 40-43Θεματικοί όροι: вторинна профілактика, hypertension, ramipril, Trinomia, поліпіл (polypill), Триномія, вторичная профилактика, раміприл, NEPTUNO study, полипил (polypill), polypill (polypill), атеросклеротическое сердечно-сосудистое заболевание, рамиприл, atherosclerotic cardiovascular disease, atorvastatin, артериальная гипертензия, исследование NEPTUNO, acetylsalicylic acid, атеросклеротичне серцево-судинне захворювання, 3. Good health, Триномия, ацетилсаліцилова кислота, аторвастатин, ацетилсалициловая кислота, дослідження NEPTUNO, артеріальна гіпертензія, secondary prevention, CNIC-Polypill
Περιγραφή αρχείου: application/pdf
Σύνδεσμος πρόσβασης: http://lu-journal.com.ua/article/view/264214
-
3Academic Journal
Πηγή: Лекарства Украины; № 2(258) (2022): приложение 1; 44-46
Medicine of Ukraine; No. 2(258) (2022): appendix 1; 44-46
Ліки України; № 2(258) (2022): додаток 1; 44-46Θεματικοί όροι: фармакоэкономический анализ, фармакоекономічний аналіз, ramipril, pharmacoeconomic analysis, поліпіл (polypill), Триномія, раміприл, использование ресурсов здравоохранения, cardiovascular disease, NEPTUNO study, use of health care resources, використання ресурсів охорони здоров'я, полипил (polypill), атеросклеротическое сердечно-сосудистое заболевание, рамиприл, atherosclerotic cardiovascular disease, atorvastatin, исследование NEPTUNO, acetylsalicylic acid, атеросклеротичне серцево-судинне захворювання, Trinomy, 3. Good health, Триномия, ацетилсаліцилова кислота, серцево-судинні захворювання, аторвастатин, сердечно-сосудистые заболевания, ацетилсалициловая кислота, дослідження NEPTUNO, polypill
Περιγραφή αρχείου: application/pdf
Σύνδεσμος πρόσβασης: http://lu-journal.com.ua/article/view/264221
-
4Academic Journal
Πηγή: Лекарства Украины; № 2(258) (2022): приложение 1; 18-21
Medicine of Ukraine; No. 2(258) (2022): appendix 1; 18-21
Ліки України; № 2(258) (2022): додаток 1; 18-21Θεματικοί όροι: пошаговый подход, cardiovascular risks, атеросклеротическое сердечно-сосудистое заболевание, ESC recommendations (2021), atherosclerotic cardiovascular disease, атеросклеротичне серцево-судинне захворювання, 3. Good health, поліпіл (polypill), prevention of cardiovascular diseases, покроковий підхід, сердечно-сосудистые риски, профилактика сердечно-сосудистых заболеваний, профілактика серцево-судинних захворювань, step-by-step approach, рекомендации ESC (2021), серцево-судинні ризики, рекомендації ESC (2021), полипил (polypill), polypill
Περιγραφή αρχείου: application/pdf
Σύνδεσμος πρόσβασης: http://lu-journal.com.ua/article/view/264095
-
5Academic Journal
Πηγή: Лекарства Украины; № 2(258) (2022): приложение 1; 35-39
Medicine of Ukraine; No. 2(258) (2022): appendix 1; 35-39
Ліки України; № 2(258) (2022): додаток 1; 35-39Θεματικοί όροι: вторинна профілактика, ramipril, Trinomia, поліпіл (polypill), acute coronary syndrome, Триномія, раміприл, вторичная профилактика, NEPTUNO study, полипил (polypill), атеросклеротическое сердечно-сосудистое заболевание, рамиприл, гострий коронарний синдром, atherosclerotic cardiovascular disease, исследование NEPTUNO, atorvastatin, acetylsalicylic acid, атеросклеротичне серцево-судинне захворювання, острый коронарный синдром, 3. Good health, Триномия, ацетилсаліцилова кислота, аторвастатин, дослідження NEPTUNO, ацетилсалициловая кислота, secondary prevention, polypill
Περιγραφή αρχείου: application/pdf
Σύνδεσμος πρόσβασης: http://lu-journal.com.ua/article/view/264210
-
6Academic Journal
Πηγή: Лекарства Украины; № 2(258) (2022): приложение 1; 47-52
Medicine of Ukraine; No. 2(258) (2022): appendix 1; 47-52
Ліки України; № 2(258) (2022): додаток 1; 47-52Θεματικοί όροι: вторинна профілактика, хронический коронарный синдром, пошаговые алгоритмы, hypertension, кардіоренальний синдром, ацетилсалицин, поліпіл (polypill), acute coronary syndrome, Триномія, кардиоренальный синдром, раміприл, вторичная профилактика, acetalis, покрокові алгоритми, полипил (polypill), chronic coronary syndrome, cardiorenal syndrome, step-by-step algorithms, атеросклеротическое сердечно-сосудистое заболевание, гострий коронарний синдром, хронічні захворювання серцево-судинної системи, atherosclerotic cardiovascular disease, артериальная гипертензия, атеросклеротичне серцево-судинне захворювання, острый коронарный синдром, хронічний коронарний синдром, acetyl, polypyl, 3. Good health, ацетилсаліцилова кислота, хронические заболевания сердечно-сосудистой системы, secondary prophylaxis, chronic diseases of the cardiovascular system, аторвастатин, артеріальна гіпертензія, polypil
Περιγραφή αρχείου: application/pdf
Σύνδεσμος πρόσβασης: http://lu-journal.com.ua/article/view/264224
-
7Academic Journal
Πηγή: Лекарства Украины; № 2(258) (2022): приложение 1; 22-27
Medicine of Ukraine; No. 2(258) (2022): appendix 1; 22-27
Ліки України; № 2(258) (2022): додаток 1; 22-27Θεματικοί όροι: хронический коронарный синдром, ACE inhibitors, рекомендации ESC, ESC recommendations, Trinomia, інгібітори АПФ, acute coronary syndrome, statins, поліпіл (polypill), Триномія, статины, coronary heart disease, рекомендації ESC, полипил (polypill), chronic coronary syndrome, атеросклеротическое сердечно-сосудистое заболевание, ишемическая болезнь сердца, гострий коронарний синдром, atherosclerotic cardiovascular disease, acetylsalicylic acid, атеросклеротичне серцево-судинне захворювання, острый коронарный синдром, хронічний коронарний синдром, 3. Good health, статини, Триномия, ацетилсаліцилова кислота, атеросклероз, atherosclerosis, ацетилсалициловая кислота, ішемічна хвороба серця, ингибиторы АПФ, polypill
Περιγραφή αρχείου: application/pdf
Σύνδεσμος πρόσβασης: http://lu-journal.com.ua/article/view/264107
-
8Academic Journal
Συγγραφείς: Г. Пушкарев, С. Мацкеплишвили
Πηγή: Патология кровообращения и кардиохирургия, Vol 25, Iss 4 (2021)
Θεματικοί όροι: депрессия, психосоциальный фактор риска, сердечно-сосудистое заболевание, социальная поддержка, социально-экономический статус, стресс, Surgery, RD1-811
Περιγραφή αρχείου: electronic resource
Relation: https://journalmeshalkin.ru/index.php/heartjournal/article/view/1023; https://doaj.org/toc/1681-3472; https://doaj.org/toc/2500-3119
Σύνδεσμος πρόσβασης: https://doaj.org/article/67670f6384fb47ac939b0586236e2e10
-
9Academic Journal
Συγγραφείς: Z. Abdurakhmanov M., B. Umarov Y., M. Abdurakhmanov M., З. Абдурахманов М., Б. Умаров Я., М. Абдурахманов М.
Πηγή: Rational Pharmacotherapy in Cardiology; Vol 17, No 4 (2021); 612-618 ; Рациональная Фармакотерапия в Кардиологии; Vol 17, No 4 (2021); 612-618 ; 2225-3653 ; 1819-6446
Θεματικοί όροι: endothelial dysfunction, cardiovascular disease, endothelial cell, biomarker, endothelial microparticles, endoglin, endocan, эндотелиальная дисфункция, сердечно-сосудистое заболевание, эндотелиальная клетка, биомаркер, эндотелиальные микрочастицы, эндокан, эндоглин
Περιγραφή αρχείου: application/pdf
Relation: https://www.rpcardio.com/jour/article/view/2544/2213; Daiber A, Steven S, Weber A, et al. Targeting vascular (endothelial) dysfunction. Br J Pharmacol. 2017;174(12):1591-619. DOI:10.1111/bph.13517.; Шабров А.В., Апресян А.Г., Добкес А.Л., и др. Современные методы оценки эндотелиальной дисфункции и возможности их применения в практической медицине. Рациональная Фармакотерапия в Кардиологии. 2016;12(6):733-42. DOI:10.20996/1819-6446-2016-12-6-733-742.; Davenport AP, Hyndman KA, Dhaun N, et al. Endothelin. Pharmacological Reviews. 2016;68(2):357418. DOI:10.1124/pr.115.011833.; Medina-Leyte DJ, Zepeda-García O, Domínguez-Pérez M, et al. Endothelial dysfunction, inflammation and coronary artery disease: potential biomarkers and promising therapeutical approaches. Int J Mol Sci. 2021;22(8):3850. DOI:10.3390/ijms22083850.; Munzel T, Gori T, Keaney JF, et al. Pathophysiological role of oxidative stress in systolic and diastolic heart failure and its therapeutic implications. Eur Heart J. 2015;36(38):2555-64. DOI:10.1093/eurheartj/ehv305.; Kaur R, Kaur M, Singh J. Endothelial dysfunction and platelet hyperactivity in type 2 diabetes mellitus: molecular insights and therapeutic strategies. Cardiovasc Diabetol. 2018;17(1):121. DOI:10.1186/s12933-018-0763-3.; Smiljic S. The clinical significance of endocardial endothelial dysfunction. Medicina (Kaunas). 2017;53(5):295-302. DOI:10.1016/j.medici.2017.08.003.; Mordi I, Mordi N, Delles C, et al. Endothelial dysfunction in human essential hypertension. Journal of Hypertension. 2016;34(8):1464-72. DOI:10.1097/HJH.0000000000000965.; Gungor ZB, Sipahioglu N, Sonmez H, et al. Endothelial dysfunction markers in low cardiovascular risk individuals: comparison of males and females. Journal of Medical Biochemistry. 2017;36(1):62-72. DOI:10.1515/jomb-2016-0030.; Talavera-Adame D. Endothelium-derived essential signals involved in pancreas organogenesis. World Journal of Experimental Medicine. 2015;5(2):40. DOI:10.5493/wjem.v5.i2.40.; Castro-Ferreira R, Cardoso R, Leite-Moreira A, et al. The role of endothelial dysfunction and inflammation in chronic venous disease. Ann Vasc Surg. 2018;46:380-93. DOI:10.1016/j.avsg.2017.06.131.; Fernandes DC, Araujo TSLS, Tanaka LY. Hemodynamic forces in the endothelium: from mechanotransduction to implications on development of atherosclerosis. In: Da Luz PL, Libby P, Chagas ACP, Laurindo FRM, eds. Endothelium and cardiovascular diseases: vascular biology and clinical syndromes. London, England: Academic Press; 2018:85-95. DOI:10.1177/0003319720946977.; Tremblay JC, Grewal AS, Pyke KE. Examining the acute effects of retrograde versus low mean shear rate on flow-mediated dilation. J Appl Physiol. 2019;126(5):1335-42. DOI:10.1152/japplphysiol.01065.2018.; Heo KS, Fujiwara K, Abe J. Shear stress and atherosclerosis. Mol Cells. 2014;37(6):435-40. DOI:10.14348/molcells.2014.0078.; Walczak M, Suraj J, Kus K, et al. Towards a comprehensive endothelial biomarkers profiling and endothelium-guided pharmacotherapy. Pharmacol Rep. 2015;67(4):771-7. DOI:10.1016/j.pharep.2015.06.008.; Strisciuglio T, De Luca S, Capuano E, et al. Endothelial dysfunction: its clinical value and methods of assessment. Current Atherosclerosis Reports. 2014;16(6):417. DOI:10.1007/s11883-0140417-1.; Balta S, Mikhailidis DP, Demirkol S, et al. Endocan: a novel inflammatory indicator in cardiovascular disease? Atherosclerosis. 2015;243(1):339-43. DOI:10.1016/j.atherosclerosis.2015.09.030.; Gifford JR, Richardson RS. CORP: ultrasound assessment of vascular function with the passive leg movement technique. J Appl Physiol. 2017;123(6):1708-20. DOI:10.1152/japplphysiol.00557.2017.; Wang XS, Yang W, Luo T, et al. Serum endocan levels are correlated with the presence and severity of coronary artery disease in patients with hypertension. Genet Test Mol Biomarkers. 2015;19(3):124-7. DOI:10.1089/gtmb.2014.0274.; Schmidt DE, Manca M, Hoefer IE. Circulating endothelial cells in coronary artery disease and acute coronary syndrome. Trends Cardiovasc Med. 2015;25(7):578-87. DOI:10.1016/j.tcm.2015.01.013.; Santilli F, Marchisio M, Lanuti P, et al. Microparticles as new markers of cardiovascular risk in diabetes and beyond. Thromb Haemost. 2016;116(2):220-34. DOI:10.1160/TH16-03-0176.; Alexandru N, Badila E, Weiss E, et al. Vascular complications in diabetes: microparticles and microparticle associated microRNAs as active players. Biochem Biophys Res Commun. 2016;472(1):1-10. DOI:10.1016/j.bbrc.2016.02.038.; Parker B, Al-Husain A, Pemberton P, et al. Suppression of inflammation reduces endothelial microparticles in active systemic lupus erythematosus. Ann Rheum Dis. 2014;73(6):1144-50. DOI:10.1136/annrheumdis-2012-203028.; Song R, Chou YI, Kong J, et al. Association of endothelial microparticle with NO, eNOS, ET-1, and fractional flow reserve in patients with coronary intermediate lesions. Biomarkers. 2015; 20(67):429-35. DOI:10.3109/1354750X.2015.1094140.; Goumans MJ, Ten Dijke P. TGF-beta signaling in control of cardiovascular function. Cold Spring Harb Perspect Biol. 2018;10(2):a022210. DOI:10.1101/cshperspect.a022210.; Jang YS, Choi IH. Contrasting roles of different endoglin forms in atherosclerosis. Immune Netw. 2014;14(5):237-40. DOI:10.4110/in.2014.14.5.237.; Jezkova K, Rathouska J, Nemeckova I, et al. High levels of soluble endoglin induce a proinflammatory and oxidativestress phenotype associated with preserved no-dependent vasodilatation in aortas from mice fed a high-fat diet. J Vasc Res. 2016;53(3-4):149-62. DOI:10.1159/000448996.; Vitverova B, Blazickova K, Najmanova I, et al. Soluble endoglin and hypercholesterolemia aggravate endothelial and vessel wall dysfunction in mouse aorta. Atherosclerosis. 2018;271:15-25. DOI:10.1016/j.atherosclerosis.2018.02.008.; Varejckova M, Gallardo-Vara E, Vicen M, et al. Soluble endoglin modulates the pro-inflammatory mediators NF-kappaB and IL-6 in cultured human endothelial cells. Life Sci. 2017;175:52-60. DOI:10.1016/j.lfs.2017.03.014.; Emeksiz HC, Bideci A, Damar C, et al. Soluble endoglin level increase occurs prior to development of subclinical structural vascular alterations in diabetic adolescents. J Clin Res Pediatr Endocrinol. 2016;8(3):313-20. DOI:10.4274/jcrpe.2906.; Gerrits T, Zandbergen M, Wolterbeek R, et al. Endoglin promotes myofibroblast differentiation and extracellular matrix production in diabetic nephropathy. Int J Mol Sci. 2020;21(20):7713. DOI:10.3390/ijms21207713.; Ikemoto T, Hojo Y, Kondo H, et al. Plasma endoglin as a marker to predict cardiovascular events in patients with chronic coronary artery diseases. Heart Vessels. 2012;27(4):344-51. DOI:10.1007/s00380-011-0163-z.; Redgrave R.E, Tual-Chalot S, Davison B.J, et el. Cardiosphere-derived cells require endoglin for paracrine-mediated angiogenesis. Stem cell reports. 2017;8(5):1287-98. DOI:10.1016/j.stemcr.2017.04.015.; Canpolat U, Kocyigit D, Yildirim A. Role of endothelial dysfunction and endocan in atherosclerosis: point of origin or end point? Angiology. 2020;71(5):477. DOI:10.1177/0003319716654627.; Rocha SF, Schiller M, Jing D, et al. Esm1 modulates endothelial tip cell behavior and vascular permeability by enhancing VEGF bioavailability. Circ Res. 2014;115(6):581-90. DOI:10.1161/CIRCRESAHA.115.304718.; Lee W, Ku S.K, Kim SW, et al. Endocan elicits severe vascular inflammatory responses in vitro and in vivo. J Cell Physiol. 2014;229(5):620-30. DOI:10.1002/jcp.24485.; Sun H, Zhang H, Li K, et al. ESM-1 promotes adhesion between monocytes and endothelial cells under intermittent hypoxia. J Cell Physiol. 2019;234(2):1512-21. DOI:10.1002/jcp.27016.; Icli A, Cure E, Cure MC, et al. Endocan levels and subclinical atherosclerosis in patients with systemic lupus erythematosus. Angiology. 2016;67(8):749-55. DOI:10.1177/0003319715616240.; De Freitas Caires N, Gaudet A, Portier L, et al. Endocan, sepsis, pneumonia, and acute respiratory distress syndrome. Crit Care. 2018;22(1):280. DOI:10.1186/s13054-018-2222-7.; Hsiao SY, Kung CT, Tsai NW, et al. Concentration and value of endocan on outcome in adult patients after severe sepsis. Clin Chim Acta. 2018;483:275-80. DOI:10.1016/j.cca.2018.05.007.; Gungor A, Palabiyik S.S, Bayraktutan Z, et al. Levels of endothelial cell-specific molecule-1 (ESM-1) in overt hypothyroidism. Endocr Res. 2016;41(4):275-80. DOI:10.3109/07435800.2015.1135443.; Cimen T, Efe TH, Akyel A, et al. Human endothelial cellspecific molecule-1 (endocan) and coronary artery disease and microvascular angina. Angiology. 2016;67(3):846-53. DOI:10.1177/0003319715625827.; Kundi H, Balun A, Cicekcioglu H, et al. Admission endocan level may be a useful predictor for in-hospital mortality and coronary severity index in patients with ST-segment elevation myocardial infarction. Angiology. 2017;68(1):46-51. DOI:10.1177/0003319716646932.; Musialowska D, Zbroch E, Koc-Zorawska E, et al. Endocan concentration in patients with primary hypertension. Angiology. 2018;69(6):483-9. DOI:10.1177/0003319717736158.; Lv Y, Zhang Y, Shi W, et al. The association between endocan levels and subclinical atherosclerosis in patients with type 2 diabetes mellitus. Am J Med Sci. 2017;353(5):433-8. DOI:10.1016/j.amjms.2017.02.004.; Balamir I, Ates I, Topcuoglu C, et al. Association of endocan, ischemia-modified albumin, and hsCRP levels with endothelial dysfunction in type 2 diabetes mellitus. Angiology. 2018;69(7):609-16. DOI:10.1177/0003319717740781.; Altintas N, Mutlu LC, Akkoyun D.C, et al. Effect of CPAP on new endothelial dysfunction marker, endocan, in people with obstructive sleep apnea. Angiology. 2016;67(4):364-74. DOI:10.1177/0003319715590558.; Yilmaz MI, Siriopol D, Saglam M, et al. Plasma endocan levels associate with inflammation, vascular abnormalities, cardiovascular events, and survival in chronic kidney disease. Kidney Int. 2014;86(6):1213-20. DOI:10.1038/ki.2014.227.; Zhao T, Kecheng Y, Zhao X, et al. The higher serum endocan levels may be a risk factor for the onset of cardiovascular disease: a meta-analysis. Med (Baltimore). 2018;97(49):e13407. DOI:10.1097/MD.0000000000013407.; https://www.rpcardio.com/jour/article/view/2544
-
10Academic Journal
Συγγραφείς: Vasquez Abanto, А.E., Vasquez Abanto, J.E.
Πηγή: HYPERTENSION; Том 13, № 2-3 (2020); 42-60
АРТЕРИАЛЬНАЯ ГИПЕРТЕНЗИЯ; Том 13, № 2-3 (2020); 42-60
АРТЕРІАЛЬНА ГІПЕРТЕНЗІЯ; Том 13, № 2-3 (2020); 42-60Θεματικοί όροι: артеріальна гіпертензія, артеріальний тиск, фактор ризику, серцево-судинне захворювання, класифікація, нові рекомендації, артериальная гипертензия, артериальное давление, фактор риска, сердечно-сосудистое заболевание, классификация, новые рекомендации, arterial hypertension, blood pressure, risk factor, cardiovascular disease, classification, new recommendations
Περιγραφή αρχείου: application/pdf
Σύνδεσμος πρόσβασης: http://hypertension.zaslavsky.com.ua/article/view/205337
-
11Academic Journal
Συγγραφείς: J. Berger S., C. Jordan O., D. Lloyd-Jones, R.S. Blumenthal
Πηγή: Rational Pharmacotherapy in Cardiology; Vol 6, No 3 (2010); 381-390 ; Рациональная Фармакотерапия в Кардиологии; Vol 6, No 3 (2010); 381-390 ; 2225-3653 ; 1819-6446 ; 10.20996/1819-6446-2010-6-3
Θεματικοί όροι: сердечно-сосудистое заболевание, шкала риска, профилактика, инфаркт миокарда
Περιγραφή αρχείου: application/pdf
Relation: https://www.rpcardio.com/jour/article/view/883/916; Lloyd-Jones D, Adams R, Carnethon M, et al. Heart disease and stroke statistics—2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2009;119:e21–181.; D’Agostino RB Sr., Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 2008;117:743–53.; National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486 –97.; Vasan RS, Sullivan LM, Wilson PW, et al. Relative importance of borderline and elevated levels of coronary heart disease risk factors. Ann Intern Med 2005;142:393– 402.; Yusuf S,Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associatedwith myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004;364:937–52.; Kannel WB, McGee D, Gordon T. A general cardiovascular risk profile: the Framingham Study. Am J Cardiol 1976;38:46 –51.; Wilson PW, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998;97:1837– 47.; U.S. Preventive Services Task Force. Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2009;150:396–404.; Pearson TA, Blair SN, Daniels SR, et al. AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update: Consensus Panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. American Heart Association Science Advisory and Coordinating Committee. Circulation 2002;106:388 –91.; D’Agostino RB, Sr., Grundy S, Sullivan LM, Wilson P. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA 2001;286:180 –7.; Brindle P, Beswick A, Fahey T, Ebrahim S. Accuracy and impact of risk assessment in the primary prevention of cardiovascular disease: a systematic review. Heart 2006;92:1752–9.; Murabito JM, D’Agostino RB, Silbershatz H, Wilson WF. Intermittent claudication. A risk profile from the Framingham Heart Study. Circulation 1997;96:44 –9.; Wolf PA, D’Agostino RB, Belanger AJ, Kannel WB. Probability of stroke: a risk profile from the Framingham study. Stroke 1991;22:312–8.; Kannel WB, D’Agostino RB, Silbershatz H, Belanger AJ, Wilson PW, Levy D. Profile for estimating risk of heart failure. Arch Intern Med 1999;159:1197–204.; Lloyd-Jones DM, Larson MG, Beiser A, Levy D. Lifetime risk of developing coronary heart disease. Lancet 1999;353:89 –92.; Lloyd-Jones DM, Leip EP, Larson MG, et al. Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age. Circulation 2006;113:791– 8.; Pencina MJ, D’Agostino RB Sr., Larson MG, Massaro JM, Vasan RS. Predicting the 30-year risk of cardiovascular disease: the Framingham Heart Study. Circulation 2009;119:3078–84.; Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227–39.; Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial–Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003;361:1149 –58.; Conroy RM, Pyorala K, Fitzgerald AP, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003;24:987–1003.; Ridker PM, Buring JE, Rifai N, Cook NR.Development and validation ofimproved algorithms forthe assessment of global cardiovascular risk in women: the Reynolds Risk Score. JAMA 2007;297:611–9.; Ridker PM, Paynter NP, Rifai N, Gaziano JM, Cook NR. C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds Risk Score for men. Circulation 2008;118:2243–51.; Woodward M, Brindle P, Tunstall-Pedoe H. Adding social deprivation and family history to cardiovascular risk assessment: the ASSIGN score from the Scottish Heart Health Extended Cohort (SHHEC). Heart 2007;93:172– 6.; Hippisley-Cox J, Coupland C, Vinogradova Y, Robson J, May M, Brindle P. Derivation and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: prospective open cohort study. BMJ 2007;335:136.; Hippisley-Cox J, Coupland C,Vinogradova Y, Robson J, Brindle P. Performance ofthe QRISK cardiovascular risk prediction algorithm in an independent UK sample of patients from general practice: a validation study. Heart 2008;94:34 –9.; Greenland P, Smith SC Jr., Grundy SM. Improving coronary heart disease risk assessment in asymptomatic people:role oftraditionalrisk factors and noninvasive cardiovasculartests. Circulation 2001;104: 1863–7.; Mora S, Redberg RF, Sharrett AR, Blumenthal RS. Enhanced risk assessment in asymptomatic individuals with exercise testing and Framingham risk scores. Circulation 2005;112:1566 –72.; Cohn JN, Duprez DA. Time to foster a rational approach to preventing cardiovascular morbid events. J Am Coll Cardiol 2008;52:327–9.; Greenland P, Lloyd-Jones D. Defining a rational approach to screening for cardiovascular risk in asymptomatic patients. J Am Coll Cardiol 2008;52:330 –2.; Fowkes FG, Murray GD, Butcher I, et al. Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: a meta-analysis. JAMA 2008;300:197–208.; Detrano R, Guerci AD, Carr JJ, et al. Coronary calcium as a predictor of coronary events in four racial or ethnic groups. N Engl J Med 2008;358:1336–45.; Lorenz MW, Markus HS, Bots ML, Rosvall M, Sitzer M. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation 2007;115:459–67.; Gibbons RJ, Balady GJ, Beasley JW, et al. ACC/AHA guidelines for exercise testing: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Exercise Testing). J Am Coll Cardiol 1997;30:260 –311.; Balady GJ, Larson MG, Vasan RS, Leip EP, O’Donnell CJ, Levy D. Usefulness of exercise testing in the prediction of coronary disease risk among asymptomatic persons as a function of the Framingham risk score. Circulation 2004;110:1920 –5.; Gaziano TA, Young CR, Fitzmaurice G, Atwood S, Gaziano JM. Laboratory-based versus non-laboratory-based method for assessment of cardiovascular disease risk: the NHANES I follow-up study cohort. Lancet 2008;371:923–31.; Berry JD, Lloyd-Jones DM, Garside DB, Greenland P. Framingham risk score and prediction of coronary heart disease death in young men. Am Heart J 2007;154:80–6.; Berry JD, Liu K, Folsom AR, et al. Prevalence and progression of subclinical atherosclerosis in younger adults with low short-term but high lifetime estimated risk for cardiovascular disease: the coronary artery risk development in young adults study and multi-ethnic study of atherosclerosis. Circulation 2009;119:382–9.; Brindle P, Emberson J, Lampe F, et al. Predictive accuracy of the Framingham coronary risk score in British men: prospective cohort study. BMJ 2003;327:1267.; Liu J, Hong Y, D’Agostino RB Sr., et al. Predictive value for the Chinese population of the Framingham CHD risk assessment tool compared with the Chinese Multi-Provincial Cohort Study. JAMA 2004;291:2591–9.; Grundy SM, D’Agostino RB Sr., Mosca L, et al. Cardiovascular risk assessment based on US cohort studies: findings from a National Heart, Lung, and Blood Institute workshop. Circulation 2001;104: 491–6.; Berger JS, Roncaglioni MC, Avanzini F, Pangrazzi I, Tognoni G, Brown DL. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA 2006;295:306 –13.; Ridker PM, Cook NR, Lee IM, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005;352:1293–304.; Graham I, Atar D, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Eur Heart J 2007;28:2375– 414.; Grundy SM, Pasternak R, Greenland P, Smith S Jr., Fuster V. Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation 1999;100: 1481–92.; https://www.rpcardio.com/jour/article/view/883
-
12Academic Journal
Συγγραφείς: Berger, J., Jordan, C., Lloyd-jones, D., Blumenthal, R.
Θεματικοί όροι: сердечно-сосудистое заболевание, шкала риска, профилактика, инфаркт миокарда
Περιγραφή αρχείου: text/html
